Mary Coleman
Investor Relations Kontakt bei CATALYST PHARMACEUTICALS, INC.
Profil
Mary Coleman is currently the Head-Investor Relations Contact at Catalyst Pharmaceuticals, Inc. She previously worked as the Senior Director-Investor Relations at Savient Pharmaceuticals, Inc., Vice President-Investor Relations & Communications at BioDelivery Sciences International, Inc., Head-Investor Relations at Agile Therapeutics, Inc., and Vice President-Investor Relations at BioXcel Therapeutics, Inc. Ms. Coleman completed her undergraduate degree at Bowling Green State University.
Aktive Positionen von Mary Coleman
| Unternehmen | Position | Beginn |
|---|---|---|
| CATALYST PHARMACEUTICALS, INC. | Investor Relations Kontakt | 16.08.2021 |
Ehemalige bekannte Positionen von Mary Coleman
| Unternehmen | Position | Ende |
|---|---|---|
| BIOXCEL THERAPEUTICS, INC. | Investor Relations Kontakt | - |
| AGILE THERAPEUTICS, INC. | Investor Relations Kontakt | - |
| BIODELIVERY SCIENCES INTERNATIONAL, INC. | Investor Relations Kontakt | - |
| SAVIENT PHARMACEUTICALS INC | Investor Relations Kontakt | - |
Ausbildung von Mary Coleman
| Bowling Green State University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| AGILE THERAPEUTICS, INC. | Health Technology |
| CATALYST PHARMACEUTICALS, INC. | Health Technology |
| BIOXCEL THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Savient Pharmaceuticals, Inc.
 Savient Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Savient Pharmaceuticals, Inc. operates as a specialty biopharmaceutical company, which develops, manufactures and markets pharmaceutical products. The company focuses on developing and commercializing KRYSTEXXA for the treatment of chronic gout in adult patients who do not respond to conventional therapy. It also sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. The company was founded in 1980 is headquartered in East Brunswick, NJ. | Health Technology |
BioDelivery Sciences International, Inc.
 BioDelivery Sciences International, Inc. Pharmaceuticals: MajorHealth Technology BioDelivery Sciences International, Inc. operates as a pharmaceutical company engaged in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. Its products include Symproic and Belbuca. The company was founded on January 6, 1997 and is headquartered in Raleigh, NC. | Health Technology |
